The generation and maintenance of serum alloantibody

Current Opinion in Immunology

Volumn 22, Issue 5, 2010, Pages 669-681

  Clatworthy, M R ^a,b,c   Espeli, M ^a,b   Torpey, N ^b   Smith, K G C ^a,b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; DONOR SPECIFIC ALLOANTIBODY; HLA ANTIBODY; HLA B ANTIGEN; IMMUNOGLOBULIN; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RITUXIMAB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ALLOIMMUNITY; ANTIBODY MEDIATED REJECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BLOOD TRANSFUSION; CD4+ T LYMPHOCYTE; CELL MIGRATION; CELL SURVIVAL; CELLULAR IMMUNITY; DRUG MEGADOSE; GENOTYPE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LYMPHOCYTE DIFFERENTIATION; MEMORY CELL; NONHUMAN; ORGAN TRANSPLANTATION; PLASMAPHERESIS; PREGNANCY; REVIEW; T LYMPHOCYTE;

ANIMALS; B-LYMPHOCYTES; GRAFT REJECTION; HUMANS; ISOANTIBODIES; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 78049260913     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2010.08.018     Document Type: Review

References (124)

1. Kissmeyer-Nielsen F., Olsen S., Petersen V.P., Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966, 2:662-665.
2. Gloor J., Cosio F., Lager D.J., Stegall M.D. The spectrum of antibody-mediated renal allograft injury: implications for treatment. Am J Transplant 2008, 8:1367-1373.
3. Einecke G., Sis B., Reeve J., Mengel M., Campbell P.M., Hidalgo L.G., Kaplan B., Halloran P.F. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009, 9:2520-2531.
4. Gaston R.S., Cecka J.M., Kasiske B.L., Fieberg A.M., Leduc R., Cosio F.C., Gourishankar S., Grande J., Halloran P., Hunsicker L., et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010, 90:68-74.
5. Colvin R.B. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007, 18:1046-1056.
6. Sis B., Jhangri G.S., Bunnag S., Allanach K., Kaplan B., Halloran P.F. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009, 9:2312-2323.
7. Pape K.A., Catron D.M., Itano A.A., Jenkins M.K. The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. Immunity 2007, 26:491-502.
8. Roozendaal R., Mempel T.R., Pitcher L.A., Gonzalez S.F., Verschoor A., Mebius R.E., von Andrian U.H., Carroll M.C. Conduits mediate transport of low-molecular-weight antigen to lymph node follicles. Immunity 2009, 30:264-276.
9. Bajenoff M., Germain R.N. B-cell follicle development remodels the conduit system and allows soluble antigen delivery to follicular dendritic cells. Blood 2009, 114:4989-4997.
10. Fang Y., Xu C., Fu Y.X., Holers V.M., Molina H. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J Immunol 1998, 160:5273-5279.
11. Barrington R.A., Pozdnyakova O., Zafari M.R., Benjamin C.D., Carroll M.C. B lymphocyte memory: role of stromal cell complement and FcgammaRIIB receptors. J Exp Med 2002, 196:1189-1199.
12. Qin D., Wu J., Vora K.A., Ravetch J.V., Szakal A.K., Manser T., Tew J.G. Fc gamma receptor IIB on follicular dendritic cells regulates the B cell recall response. J Immunol 2000, 164:6268-6275.
13. Cinamon G., Zachariah M.A., Lam O.M., Foss F.W., Cyster J.G. Follicular shuttling of marginal zone B cells facilitates antigen transport. Nat Immunol 2008, 9:54-62.
14. Carrasco Y.R., Batista F.D. B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node. Immunity 2007, 27:160-171.
15. Junt T., Moseman E.A., Iannacone M., Massberg S., Lang P.A., Boes M., Fink K., Henrickson S.E., Shayakhmetov D.M., Di Paolo N.C., et al. Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature 2007, 450:110-114.
16. Phan T.G., Grigorova I., Okada T., Cyster J.G. Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nat Immunol 2007, 8:992-1000.
17. Qi H., Egen J.G., Huang A.Y., Germain R.N. Extrafollicular activation of lymph node B cells by antigen-bearing dendritic cells. Science 2006, 312:1672-1676.
18. Bergtold A., Desai D.D., Gavhane A., Clynes R. Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. Immunity 2005, 23:503-514.
19. Mueller S.N., Germain R.N. Stromal cell contributions to the homeostasis and functionality of the immune system. Nat Rev Immunol 2009, 9:618-629.
20. Radbruch A., Muehlinghaus G., Luger E.O., Inamine A., Smith K.G., Dorner T., Hiepe F. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006, 6:741-750.
21. Thaunat O., Field A.C., Dai J., Louedec L., Patey N., Bloch M.F., Mandet C., Belair M.F., Bruneval P., Meilhac O., et al. Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response. Proc Natl Acad Sci USA 2005, 102:14723-14728.
22. Kerjaschki D., Regele H.M., Moosberger I., Nagy-Bojarski K., Watschinger B., Soleiman A., Birner P., Krieger S., Hovorka A., Silberhumer G., et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol 2004, 15:603-612.
23. Wehner J.R., Fox-Talbot K., Halushka M.K., Ellis C., Zachary A.A., Baldwin W.M. B cells and plasma cells in coronaries of chronically rejected cardiac transplants. Transplantation 2010, 89:1141-1148.
24. Baddoura F.K., Nasr I.W., Wrobel B., Li Q., Ruddle N.H., Lakkis F.G. Lymphoid neogenesis in murine cardiac allografts undergoing chronic rejection. Am J Transplant 2005, 5:510-516.
25. Claas F.H., Roelen D.L., Mulder A., Doxiadis I.I., Oudshoorn M., Heemskerk M. Differential immunogenicity of HLA class I alloantigens for the humoral versus the cellular immune response: " towards tailor-made HLA mismatching" Hum Immunol 2006, 67:424-429.
26. Doxiadis I.I., Smits J.M., Schreuder G.M., Persijn G.G., van Houwelingen H.C., van Rood J.J., Claas F.H. Association between specific HLA combinations and probability of kidney allograft loss: the taboo concept. Lancet 1996, 348:850-853.
27. Dankers M.K., Roelen D.L., Van Der Meer-Prins E.M., De Lange P., Korfage N., Smits J.M., Persijn G.G., Welsh K.I., Doxiadis I.I., Claas F.H. Differential immunogenicity of HLA mismatches: HLA-A2 versus HLA-A28. Transplantation 2003, 75:418-420.
28. Dankers M.K., Witvliet M.D., Roelen D.L., de Lange P., Korfage N., Persijn G.G., Duquesnoy R., Doxiadis I.I., Claas F.H. The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched human leukocyte antigens. Transplantation 2004, 77:1236-1239.
29. Kosmoliaptsis V., Bradley J.A., Sharples L.D., Chaudhry A., Key T., Goodman R.S., Taylor C.J. Predicting the immunogenicity of human leukocyte antigen class I alloantigens using structural epitope analysis determined by HLAMatchmaker. Transplantation 2008, 85:1817-1825.
30. Kosmoliaptsis V., Chaudhry A.N., Sharples L.D., Halsall D.J., Dafforn T.R., Bradley J.A., Taylor C.J. Predicting HLA class I alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation 2009, 88:791-798.
31. Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005, 365:1570-1576.
32. Zwirner N.W., Marcos C.Y., Mirbaha F., Zou Y., Stastny P. Identification of MICA as a new polymorphic alloantigen recognized by antibodies in sera of organ transplant recipients. Hum Immunol 2000, 61:917-924.
33. Zou Y., Stastny P., Susal C., Dohler B., Opelz G. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007, 357:1293-1300.
34. Zou Y., Heinemann F.M., Grosse-Wilde H., Sireci G., Wang Z., Lavingia B., Stastny P. Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. Hum Immunol 2006, 67:230-237.
35. Quiroga I., Salio M., Koo D.D., Cerundolo L., Shepherd D., Cerundolo V., Fuggle S.V. Expression of MHC class I-related Chain B (MICB) molecules on renal transplant biopsies. Transplantation 2006, 81:1196-1203.
36. Carter V., Shenton B.K., Jaques B., Turner D., Talbot D., Gupta A., Chapman C.E., Matthews C.J., Cavanagh G. Vimentin antibodies: a non-HLA antibody as a potential risk factor in renal transplantation. Transplant Proc 2005, 37:654-657.
37. Dragun D., Muller D.N., Brasen J.H., Fritsche L., Nieminen-Kelha M., Dechend R., Kintscher U., Rudolph B., Hoebeke J., Eckert D., et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005, 352:558-569.
38. Sun Q., Liu Z., Chen J., Chen H., Wen J., Cheng D., Li L. Circulating anti-endothelial cell antibodies are associated with poor outcome in renal allograft recipients with acute rejection. Clin J Am Soc Nephrol 2008, 3:1479-1486.
39. Sutherland S.M., Li L., Sigdel T.K., Wadia P.P., Miklos D.B., Butte A.J., Sarwal M.M. Protein microarrays identify antibodies to protein kinase Czeta that are associated with a greater risk of allograft loss in pediatric renal transplant recipients. Kidney Int 2009, 76:1277-1283.
40. Porcheray F., Devito J., Yeap B.Y., Xue L., Dargon I., Paine R., Girouard T.C., Saidman S.L., Colvin R.B., Wong W., et al. Chronic humoral rejection of human kidney allografts associates with broad autoantibody responses. Transplantation 2010, 89:1239-1246.
41. Collins Z.V., Arnold P.F., Peetoom F., Smith G.S., Walford R.L. A naturally occurring monospecific anti-HL-A8 isoantibody. Tissue Antigens 1973, 3:358-363.
42. Morales-Buenrostro L.E., Terasaki P.I., Marino-Vazquez L.A., Lee J.H., El-Awar N., Alberu J. " Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008, 86:1111-1115.
43. Hirata A.A., Terasaki P.I. Cross-reactions between streptococcal M proteins and human transplantation antigens. Science 1970, 168:1095-1096.
44. Sanfilippo F., Vaughn W.K., Bollinger R.R., Spees E.K. Comparative effects of pregnancy, transfusion, and prior graft rejection on sensitization and renal transplant results. Transplantation 1982, 34:360-366.
45. Lo Y.M., Lo E.S., Watson N., Noakes L., Sargent I.L., Thilaganathan B., Wainscoat J.S. Two-way cell traffic between mother and fetus: biologic and clinical implications. Blood 1996, 88:4390-4395.
46. Suciu-Foca N., Reed E., Rohowsky C., Kung P., King D.W. Anti-idiotypic antibodies to anti-HLA receptors induced by pregnancy. Proc Natl Acad Sci USA 1983, 80:830-834.
47. Regan L., Braude P.R., Hill D.P. A prospective study of the incidence, time of appearance and significance of anti-paternal lymphocytotoxic antibodies in human pregnancy. Hum Reprod 1991, 6:294-298.
48. van Kampen C.A., Versteeg-vd Voort Maarschalk M.F., Langerak-Langerak J., Roelen D.L., Claas F.H. Kinetics of the pregnancy-induced humoral and cellular immune response against the paternal HLA class I antigens of the child. Hum Immunol 2002, 63:452-458.
49. Bianchi D.W., Zickwolf G.K., Weil G.J., Sylvester S., DeMaria M.A. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc Natl Acad Sci USA 1996, 93:705-708.
50. SivaSai K.S., Jendrisak M., Duffy B.F., Phelan D., Ravenscraft M., Howard T., Mohanakumar T. Chimerism in peripheral blood of sensitized patients waiting for renal transplantation: clinical implications. Transplantation 2000, 69:538-544.
51. Phan T.G., Green J.A., Gray E.E., Xu Y., Cyster J.G. Immune complex relay by subcapsular sinus macrophages and noncognate B cells drives antibody affinity maturation. Nat Immunol 2009, 10:786-793.
52. Dankers M.K., Roelen D.L., Nagelkerke N.J., de Lange P., Persijn G.G., Doxiadis I.I., Claas F.H. The HLA-DR phenotype of the responder is predictive of humoral response against HLA class I antigens. Hum Immunol 2004, 65:13-19.
53. Sanfilippo F., Vaughn W.K., Bollinger R.R., Spees E.K. The influence of pretransplant transfusions, using different blood products, on patient sensitization and renal allograft survival. Transplantation 1984, 37:350-356.
54. Sanfilippo F., Spees E.K., Vaughn W.K. The timing of pretransplant transfusions and renal allograft survival. Transplantation 1984, 37:344-350.
55. Scornik J.C., Schold J.D., Bucci M., Meier-Kriesche H.U. Effects of blood transfusions given after renal transplantation. Transplantation 2009, 87:1381-1386.
56. Opelz G., Graver B., Mickey M.R., Terasaki P.I. Lymphocytotoxic antibody responses to transfusions in potential kidney transplant recipients. Transplantation 1981, 32:177-183.
57. Scornik J.C., Brunson M.E., Howard R.J., Pfaff W.W. Alloimmunization, memory, and the interpretation of crossmatch results for renal transplantation. Transplantation 1992, 54:389-394.
58. Terasaki P.I., Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004, 4:438-443.
59. Hourmant M., Cesbron-Gautier A., Terasaki P.I., Mizutani K., Moreau A., Meurette A., Dantal J., Giral M., Blancho G., Cantarovich D., et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005, 16:2804-2812.
60. Fuller T.C., Fuller A. The humoral immune response against an HLA class I allodeterminant correlates with the HLA-DR phenotype of the responder. Transplantation 1999, 68:173-182.
61. McCarty G.A., King L.B., Sanfilippo F. Autoantibodies to nuclear, cytoplasmic, and cytoskeletal antigens in renal allograft rejection. Transplantation 1984, 37:446-451.
62. Khakhar A.K., Shahinian V.B., House A.A., Muirhead N., Hollomby D.J., Leckie S.H., McAlister V.C., Chin J.L., Jevnikar A.M., Luke P.P. The impact of allograft nephrectomy on percent panel reactive antibody and clinical outcome. Transplant Proc 2003, 35:862-863.
63. Matinlauri I.H., Kyllonen L.E., Eklund B.H., Koskimies S.A., Salmela K.T. Weak humoral posttransplant alloresponse after a well-HLA-matched cadaveric kidney transplantation. Transplantation 2004, 78:198-204.
64. Aiello F.B., Calabrese F., Rigotti P., Furian L., Marino S., Cusinato R., Valente M. Acute rejection and graft survival in renal transplanted patients with viral diseases. Mod Pathol 2004, 17:189-196.
65. Toyoda M., Galfayan K., Galera O.A., Petrosian A., Czer L.S., Jordan S.C. Cytomegalovirus infection induces anti-endothelial cell antibodies in cardiac and renal allograft recipients. Transpl Immunol 1997, 5:104-111.
66. Zanone M.M., Favaro E., Quadri R., Miceli I., Giaretta F., Romagnoli R., David E., Perin P.C., Salizzoni M., Camussi G. Association of cytomegalovirus infections with recurrence of humoral and cellular autoimmunity to islet autoantigens and of type 1 diabetes in a pancreas transplanted patient. Transpl Int 2010, 23:333-337.
67. Forman J.P., Tolkoff-Rubin N., Pascual M., Lin J., Hepatitis C. acute humoral rejection, and renal allograft survival. J Am Soc Nephrol 2004, 15:3249-3255.
68. Locke J.E., Zachary A.A., Warren D.S., Segev D.L., Houp J.A., Montgomery R.A., Leffell M.S. Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant 2009, 9:2136-2139.
69. Land W.G. The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation 2005, 79:505-514.
70. Kim B.S., Lim S.W., Li C., Kim J.S., Sun B.K., Ahn K.O., Han S.W., Kim J., Yang C.W. Ischemia-reperfusion injury activates innate immunity in rat kidneys. Transplantation 2005, 79:1370-1377.
71. Leemans J.C., Stokman G., Claessen N., Rouschop K.M., Teske G.J., Kirschning C.J., Akira S., van der Poll T., Weening J.J., Florquin S. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest 2005, 115:2894-2903.
72. Kaczorowski D.J., Nakao A., Mollen K.P., Vallabhaneni R., Sugimoto R., Kohmoto J., Tobita K., Zuckerbraun B.S., McCurry K.R., Murase N., et al. Toll-like receptor 4 mediates the early inflammatory response after cold ischemia/reperfusion. Transplantation 2007, 84:1279-1287.
73. Knight R.J., Dikman S., Liu H., Martinelli G.P. Cold ischemic injury accelerates the progression to chronic rejection in a rat cardiac allograft model. Transplantation 1997, 64:1102-1107.
74. Harley I.T., Kaufman K.M., Langefeld C.D., Harley J.B., Kelly J.A. Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nat Rev Genet 2009, 10:285-290.
75. Pritchard N.R., Smith K.G. B cell inhibitory receptors and autoimmunity. Immunology 2003, 108:263-273.
76. Xiang Z., Cutler A.J., Brownlie R.J., Fairfax K., Lawlor K.E., Severinson E., Walker E.U., Manz R.A., Tarlinton D.M., Smith K.G.C. FcγRIIB controls bone marrow plasma cell persistence and apoptosis. Nat Immunol 2007, 8:419-429.
77. Floto R.A., Clatworthy M.R., Heilbronn K.R., Rosner D.R., MacAry P.A., Rankin A., Lehner P.J., Ouwehand W.H., Allen J.M., Watkins N.A., et al. Loss of function of a lupus-associated FcγRIIB polymorphism through exclusion from lipid rafts. Nat Med 2005, 11:1056-1058.
78. Smith K.G., Clatworthy M.R. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol 2010, 10:328-343.
79. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., Tschopp J., Browning J.L. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710.
80. Pers J.O., Daridon C., Devauchelle V., Jousse S., Saraux A., Jamin C., Youinou P. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005, 1050:34-39.
81. Xu H., He X., Sun J., Shi D., Zhu Y., Zhang X. The expression of B-cell activating factor belonging to tumor necrosis factor superfamily (BAFF) significantly correlated with C4D in kidney allograft rejection. Transplant Proc 2009, 41:112-116.
82. Bloom D., Chang Z., Pauly K., Kwun J., Fechner J., Hayes C., Samaniego M., Knechtle S. BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am J Transplant 2009, 9:1835-1845.
83. Martin J., Worthington J., Harris S., Martin S. The influence of class II transactivator and interleukin-6 polymorphisms on the production of antibodies to donor human leucocyte antigen mismatches in renal allograft recipients. Int J Immunogenet 2009, 36:235-239.
84. Bossen C., Cachero T.G., Tardivel A., Ingold K., Willen L., Dobles M., Scott M.L., Maquelin A., Belnoue E., Siegrist C.A., et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 2008, 111:1004-1012.
85. Garcia De Vinuesa C., Gulbranson-Judge A., Khan M., O'Leary P., Cascalho M., Wabl M., Klaus G.G., Owen M.J., MacLennan I.C.M. Dendritic cells associated with plasmablast survival. Eur J Immunol 1999, 29:3712-3721.
86. Mohr E., Serre K., Manz R.A., Cunningham A.F., Khan M., Hardie D.L., Bird R., MacLennan I.C. Dendritic cells and monocyte/macrophages that create the IL-6/APRIL-rich lymph node microenvironments where plasmablasts mature. J Immunol 2009, 182:2113-2123.
87. Huard B., McKee T., Bosshard C., Durual S., Matthes T., Myit S., Donze O., Frossard C., Chizzolini C., Favre C., et al. APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. J Clin Invest 2008, 118:2887-2895.
88. Tokoyoda K., Egawa T., Sugiyama T., Choi B.I., Nagasawa T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 2004, 20:707-718.
89. Winter O., Moser K., Mohr E., Zotos D., Kaminski H., Szyska M., Roth K., Wong D.M., Dame C., Tarlinton D.M., et al. Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow. Blood 2010, 116:1867-1875.
90. Xu X., Shi B., Cai M., Han Y., Wang Q., Xu L., Xiao L., Zhou W. A retrospective study of plasma cell infiltrates in explanted renal allografts. Transplant Proc 2008, 40:1366-1370.
91. Thaunat O., Patey N., Caligiuri G., Gautreau C., Mamani-Matsuda M., Mekki Y., Dieu-Nosjean M.C., Eberl G., Ecochard R., Michel J.B., et al. Chronic rejection triggers the development of an aggressive intragraft immune response through recapitulation of lymphoid organogenesis. J Immunol 2010, 185:717-728.
92. Martin L., Charon-Barra C., Bocrie O., Guignier F., D'Athis P., Dautin G., de la Vega M.F., Justrabo E., Rifle G., Mousson C. Detection of plasma cells, C4d deposits and donor-specific antibodies on sequential graft biopsies of renal transplant recipients with chronic dysfunction. Transpl Immunol 2010, 22:110-114.
93. Perry D.K., Pollinger H.S., Burns J.M., Rea D., Ramos E., Platt J.L., Gloor J.M., Stegall M.D. Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG. Am J Transplant 2008, 8:133-143.
94. Dorner M., Brandt S., Tinguely M., Zucol F., Bourquin J.P., Zauner L., Berger C., Bernasconi M., Speck R.F., Nadal D. Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology 2009, 128:573-579.
95. Rafei M., Hsieh J., Fortier S., Li M., Yuan S., Birman E., Forner K., Boivin M.N., Doody K., Tremblay M., et al. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood 2008, 112:4991-4998.
96. Mulder A., Eijsink C., Kardol M.J., Franke-van Dijk M.E., van der Burg S.H., Kester M., Doxiadis I.I., Claas F.H. Identification, isolation, and culture of HLA-A2-specific B lymphocytes using MHC class I tetramers. J Immunol 2003, 171:6599-6603.
97. Zachary A.A., Kopchaliiska D., Montgomery R.A., Leffell M.S. HLA-specific B cells: I. A method for their detection, quantification, and isolation using HLA tetramers. Transplantation 2007, 83:982-988.
98. Maruyama M., Lam K.P., Rajewsky K. Memory B-cell persistence is independent of persisting immunizing antigen. Nature 2000, 407:636-642.
99. Gray D., Skarvall H. B-cell memory is short-lived in the absence of antigen. Nature 1988, 336:70-73.
100. Gray D. A role for antigen in the maintenance of immunological memory. Nat Rev Immunol 2002, 2:60-65.
101. Fillatreau S., Sweenie C.H., McGeachy M.J., Gray D., Anderton S.M. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002, 3:944-950.
102. Blair P.A., Norena L.Y., Flores-Borja F., Rawlings D.J., Isenberg D.A., Ehrenstein M.R., Mauri C. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010, 32:129-140.
103. Bray R.A., Nolen J.D., Larsen C., Pearson T., Newell K.A., Kokko K., Guasch A., Tso P., Mendel J.B., Gebel H.M. Transplanting the highly sensitized patient: the emory algorithm. Am J Transplant 2006, 6:2307-2315.
104. Cai J., Terasaki P.I. Post-transplantation antibody monitoring and HLA antibody epitope identification. Curr Opin Immunol 2008, 20:602-606.
105. Hidalgo L.G., Campbell P.M., Sis B., Einecke G., Mengel M., Chang J., Sellares J., Reeve J., Halloran P.F. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009, 9:2532-2541.
106. Montgomery R.A. Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols. Am J Transplant 2010, 10:449-457.
107. Jordan S.C., Vo A.A., Tyan D., Nast C.C., Toyoda M. Current approaches to treatment of antibody-mediated rejection. Pediatr Transplant 2005, 9:408-415.
108. Warren D.S., Montgomery R.A. Incompatible kidney transplantation: lessons from a decade of desensitization and paired kidney exchange. Immunol Res 2010, 47:257-264.
109. Montgomery R.A., Zachary A.A., Racusen L.C., Leffell M.S., King K.E., Burdick J., Maley W.R., Ratner L.E. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000, 70:887-895.
110. Shah A., Nadasdy T., Arend L., Brennan J., Leong N., Coppage M., Orloff M., Demme R., Zand M.S. Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation 2004, 77:1399-1405.
111. Gloor J.M., Winters J.L., Cornell L.D., Fix L.A., DeGoey S.R., Knauer R.M., Cosio F.G., Gandhi M.J., Kremers W., Stegall M.D. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010, 10:582-589.
112. Vo A.A., Peng A., Toyoda M., Kahwaji J., Cao K., Lai C.H., Reinsmoen N.L., Villicana R., Jordan S.C. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010, 89:1095-1102.
113. Luke P.P., Scantlebury V.P., Jordan M.L., Vivas C.A., Hakala T.R., Jain A., Somani A., Fedorek S., Randhawa P., Shapiro R. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 2001, 72:419-422.
114. Jordan S.C., Vo A.A., Toyoda M., Tyan D., Nast C.C. Post-transplant therapy with high-dose intravenous gammaglobulin: applications to treatment of antibody-mediated rejection. Pediatr Transplant 2005, 9:155-161.
115. Jordan S.C., Toyoda M., Vo A.A. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 2009, 88:1-6.
116. Garrett H.E., Groshart K., Duvall-Seaman D., Combs D., Suggs R. Treatment of humoral rejection with rituximab. Ann Thorac Surg 2002, 74:1240-1242.
117. Becker Y.T., Becker B.N., Pirsch J.D., Sollinger H.W. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004, 4:996-1001.
118. Sawada T., Fuchinoue S., Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 2002, 74:1207-1210.
119. Sonnenday C.J., Warren D.S., Cooper M., Samaniego M., Haas M., King K.E., Shirey R.S., Simpkins C.E., Montgomery R.A. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004, 4:1315-1322.
120. Segev D.L., Simpkins C.E., Warren D.S., King K.E., Shirey R.S., Maley W.R., Melancon J.K., Cooper M., Kozlowski T., Montgomery R.A. ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. Am J Transplant 2005, 5:2570-2575.
121. Zand M.S., Vo T., Huggins J., Felgar R., Liesveld J., Pellegrin T., Bozorgzadeh A., Sanz I., Briggs B.J. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005, 79:1507-1515.
122. Ramos E.J., Pollinger H.S., Stegall M.D., Gloor J.M., Dogan A., Grande J.P. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 2007, 7:402-407.
123. Bachler K., Amico P., Honger G., Bielmann D., Hopfer H., Mihatsch M.J., Steiger J., Schaub S. Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor-specific HLA-antibodies. Am J Transplant 2010, 10:1254-1262.
124. Perry D.K., Burns J.M., Pollinger H.S., Amiot B.P., Gloor J.M., Gores G.J., Stegall M.D. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009, 9:201-209.